Acerta Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Acerta Pharma - overview
Location
-, -, Netherlands
Primary Industry
Healthcare
About
Acerta Pharma is a pharmaceutical company focused on developing innovative therapies for hematological malignancies, utilizing multi-omic platforms to enhance treatment efficacy and patient outcomes in blood cancer care. Acerta Pharma, founded by Ahmed Hamdy, specializes in hematology product development. The company was acquired by AstraZeneca in December 2015, receiving USD 2. 5 billion for a 55 percent majority stake.
Its headquarters is located in the Netherlands. Ahmed Hamdy serves as both CEO and founder. Acerta Pharma specializes in developing innovative therapies for hematological malignancies, focusing on investigational agents that target cancer cells and boost the immune system's capacity to eliminate cancer. Their primary offerings include first-in-class and best-in-class medicines for various blood cancers, aimed at addressing significant unmet medical needs.
The company employs advanced multi-omic platforms to facilitate the optimization of targeted therapies and markets its products to healthcare providers across North America, Europe, and parts of Asia. In 2023, Acerta Pharma generated revenue of USD 930. 34 mn, with an EBITDA of USD 709. 81 mn.
The company generates revenue through strategic collaborations with AstraZeneca and other partners, primarily focusing on hematology products, and operates through direct sales and established distribution channels. Acerta Pharma plans to leverage recent funding from its acquisition by AstraZeneca to enhance its product pipeline and expand into new markets. The company aims to launch several new products targeting blood cancers by 2025 and is focusing on expanding its presence in Asia and Europe. The acquisition in December 2015 will support these initiatives by providing the necessary capital for development and commercialization efforts.
Current Investors
BioGeneration Ventures, BOM Brabant Ventures
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Home Healthcare, Nursing Homes & Assisted Living, Pharmaceutical Research & Development
Website
www.acerta-pharma.com
Total Amount Raised
Subscriber access only
Acerta Pharma - timeline of key events
Acerta Pharma - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | 22,842,000 | 60,121,000 | 192,932,000 | 457,940,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | 163.2% | 220.9% | 137.4% | - | - | - |
| EBITDA (USD) | - | - | (193,498,000) | (607,437,000) | 560,569,000 | (582,950,000) | (34,271,000) | 67,397,000 | 336,859,000 | - | - | - |
| Operating Income (USD) | - | - | (193,806,000) | (607,925,000) | 560,569,000 | (583,638,000) | (35,274,000) | 66,476,000 | 336,493,000 | - | - | - |
| Operating Margin | - | - | - | - | - | (2555.1%) | (58.7%) | 34.5% | 73.5% | - | - | - |
| % EBITDA Margin | - | - | - | - | - | (2552.1%) | (57.0%) | 34.9% | 73.6% | - | - | - |
| NET Income (USD) | (13,612,859.015) | (96,118,010.197) | (718,728,000) | (465,094,000) | 420,813,000 | (443,039,000) | (24,906,000) | 65,126,000 | 267,192,000 | - | - | - |
| % Net Margin | - | - | - | - | - | (1939.6%) | (41.4%) | 33.8% | 58.3% | - | - | - |
Acerta Pharma - employee data
Acerta Pharma - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer (CEO) and Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.